Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
Authors
Keywords
Sunitinib, Ambulatory Blood Pressure Monitoring, Pazopanib, Axitinib, Akaike Information Criterion
Journal
CLINICAL PHARMACOKINETICS
Volume 54, Issue 4, Pages 397-407
Publisher
Springer Nature
Online
2014-10-25
DOI
10.1007/s40262-014-0207-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Bayesian Methods for Pharmacokinetic/Pharmacodynamic Modeling of Pazopanib-Induced Increases in Blood Pressure and Transaminases
- (2013) A. Benjamin Suttle et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
- (2012) Roger B. Cohen et al. INVESTIGATIONAL NEW DRUGS
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
- (2010) A Lindauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- VEGF kinase inhibitors: how do they cause hypertension?
- (2009) Pankaj Bhargava AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
- (2009) M. L. Maitland et al. CLINICAL CANCER RESEARCH
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started